Decheng Capital’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Decheng Capital’s Portfolio ZNTL Stock Details ZNTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.42M	Hold	1,323,327	–	–	0.88%	11
2026 Q1	$3.1M	Hold	1,323,327	–	–	0.47%	12
2025 Q4	$1.79M	Hold	1,323,327	–	–	0.24%	15
2025 Q3	$2M	Hold	1,323,327	–	–	0.35%	16
2025 Q2	$1.54M	Sell	1,323,327 -696,435	-34%	-$919K	0.39%	16
2025 Q1	$3.21M	Sell	2,019,762 -318,333	-14%	-$686K	0.9%	18
2024 Q4	$7.08M	Sell	2,338,095 -770,000	-25%	-$2.52M	1.52%	14
2024 Q3	$11.4M	Buy	3,108,095 +37,653	+1%	+$137K	2.71%	7
2024 Q2	$12.6M	Buy	3,070,442 +970,859	+46%	+$10.8M	3.85%	4
2024 Q1	$33.1M	Hold	2,099,583	–	–	4.44%	3
2023 Q4	$31.8M	Buy	+2,099,583	New	+$30.6M	8.89%	2

Other funds holding ZNTL

5VM

5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Decheng Capital's ZNTL Position: Q2 2026 in Review

Decheng Capital held its Zentalis Pharmaceuticals (ZNTL) position steady in Q2 2026 at 1,323,327 shares worth $6.42M. The position accounts for 0.88% of the portfolio, ranked #11.

Decheng Capital first reported a position in ZNTL in Q4 2023 and has held it in 11 quarters since. The position peaked at $33.1M in Q1 2024. 114 funds tracked by Wall St. Rank hold ZNTL as of Q2 2026.

Decheng Capital held 1,323,327 shares of Zentalis Pharmaceuticals worth $6.42M as of Q2 2026.
Decheng Capital left its Zentalis Pharmaceuticals share count unchanged in Q2 2026.
Zentalis Pharmaceuticals made up 0.88% of Decheng Capital's portfolio in Q2 2026, its #11 holding.
Decheng Capital first reported a position in Zentalis Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
Decheng Capital's Zentalis Pharmaceuticals position peaked at $33.1M in Q1 2024.
114 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2026.

Based on Decheng Capital's 13F filing for Q2 2026, filed 14 Aug 2026.